



NDA 206356/S-03

SUPPLEMENT APPROVAL

Swedish Orphan Biovitrum, Inc.
Attention: Matthew Boyd
Vice President, Head of Regulatory North America
890 Winter Street, Suite 115
Waltham, MA 02451

Dear Mr. Boyd:

Please refer to your Supplemental New Drug Application (sNDA), dated October 31, 2016 and received November 1, 2016, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for ORFADIN® (nitisinone) oral suspension.

This Prior Approval supplemental new drug application proposes the following updates to the labelling for ORFADIN:

- 1) Updating the prescribing information (PI) section 2.1 to add the option of once-daily dosing for patients 5 years of age and older who have undetectable serum and urine succinylacetone concentrations after a minimum of 4 weeks on a stable dosage of nitisinone, in addition to the currently labeled twice-daily dosing regimen
- 2) Updating PI section 13.1 with results from a Tg.rasH2 mouse carcinogenicity study.

APPROVAL & LABELING

We completed our review of the supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at: <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of the labeling must be identical to the enclosed labeling (i.e., text for the package insert), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at:

<http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because this drug product for this indication has an orphan drug designation, you are exempt from this requirement.

POSTMARKETING COMMITMENTS SUBJECT TO REPORTING REQUIREMENTS UNDER SECTION 506B

We remind you of your postmarketing commitments:

- 3264-1 Long-term assessment of pharmacodynamic response and pharmacokinetics of ORFADIN given under a once-daily dosage regimen in treatment-naïve and treatment-experienced patients with hereditary tyrosinemia type 1 (HT-1) based on data from the ongoing Sobi.NTBC-005-study.

The timetable you submitted on September 1, 2017, states that you will conduct this study according to the following schedule:

Final Protocol Submission:	07/2018
Study/Trial Completion:	09/2019
Final Report Submission:	09/2020

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

OPDP Regulatory Project Manager
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at: <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf>).

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at: <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>. Information and Instructions for completing the form can be found at: <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call LCDR Hong Vu, Regulatory Project Manager, at (301) 796-7401.

Sincerely,

{See appended electronic signature page}

Lisa M. Soule, M.D.
Acting Associate Director
Division of Gastroenterology and Inborn Errors
Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling
Instructions for Use

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

LISA M SOULE
09/01/2017